Investor's Business Daily on MSN7h
BioNTech Stock Got A IBD RS Rating Lift
How Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
The Analyst Landscape: 17 Takes On BioNTech
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Analysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...
Strategic Acquisition and Oncology Focus Justify BioNTech’s Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
Zacks.com on MSN11h
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
Mena FN20h
BioNTech purchases Chinese biotechnology company to improve oncology strategy
(MENAFN) BioNTech signed an agreement to buy Biotheus, which is a Chinese biotechnology firm, for USD800 million to further enhance its treatment of tumors, stated the German medicinal producer ...